Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

(Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

What UBS says about Novo Nordisk. UBS analyst Matthew Weston removed his buy rating on Novo Nordisk stock this morning, downgrading the shares to neutr ...